There are 2789 resources available
1321P - Real-world treatments and clinical outcomes in advanced NSCLC without actionable mutations after introduction of immunotherapy (IO) in Japan
Presenter: Hiroshi Nokihara
Session: ePoster Display
1322P - Development and external validation of a novel four-gene-pair signature for predicting clinical response to anti-PD-1 immunotherapy of non-small cell lung cancer
Presenter: Chengming Liu
Session: ePoster Display
1323P - Immunotherapy for PDL1-high (TPS≥50%) metastatic NSCLC: Results in real-world oncology practice
Presenter: Drazena Srdic
Session: ePoster Display
1471P - Overall survival by BRCA and ATM mutation status in patients with metastatic pancreatic cancer: Findings from the PRIOR-2 study
Presenter: Gboyega Adeboyeje
Session: ePoster Display
1472P - Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of response to first-line therapy: The KRASCIPANC study
Presenter: Camille Evrard
Session: ePoster Display
1473P - Gender differences in treatment allocation and survival in a real-world metastatic pancreatic cancer cohort
Presenter: Esther Pijnappel
Session: ePoster Display
1326P - Combination of stereotactic ablative radiotherapy with anti-PD-1 in oligoprogressive disease: Final results of a prospective multicenter study
Presenter: Juan Zafra Martín
Session: ePoster Display
1475P - Results of a randomized, double-blind, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel ± olaratumab in treatment-naïve patients with unresectable metastatic pancreatic cancer
Presenter: Faithlore Gardner
Session: ePoster Display